{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:27:44Z","timestamp":1791898064186,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Gregory M.\u00a0Kiez and Mehmet Kutman Foundation","award":["T32GM007205"],"award-info":[{"award-number":["T32GM007205"]}]},{"name":"Gregory M.\u00a0Kiez and Mehmet Kutman Foundation","award":["F30CA213666"],"award-info":[{"award-number":["F30CA213666"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We and others have identified mutually exclusive molecular subgroups of meningiomas; however, the implications of this classification for clinical prognostication remain unclear. Integrated genomic and epigenomic analyses implicate unique oncogenic processes associated with each subgroup, suggesting the potential for divergent clinical courses. The aim of this study was to understand the associated clinical outcomes of each subgroup, as this could optimize treatment for patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed outcome data for 469 meningiomas of known molecular subgroup, including extent of resection, postoperative radiation, surveillance imaging, and time to recurrence, when applicable. Statistical relationships between outcome variables and subgroup were assessed. Features previously associated with recurrence were further investigated after stratification by subgroup. We used Kaplan\u2013Meier analyses to compare progression-free survival, and identified factors significantly associated with recurrence using Cox proportional hazards modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Meningioma molecular subgroups exhibited divergent clinical courses at 2 years of follow-up, with several aggressive subgroups (NF2, PI3K, HH, tumor necrosis factor receptor\u2013associated factor 7 [TRAF7]) recurring at an average rate of 22 times higher than others (KLF4, POLR2A, SMARCB1). PI3K-activated tumors recurred earlier than other subgroups but had intermediate long-term outcome. Among low-grade tumors, HH and TRAF7 meningiomas exhibited elevated recurrence compared with other subgroups. Recurrence of NF2 tumors was associated with male sex, high grade, and elevated Ki-67. Multivariate analysis identified molecular subgroup as an independent predictor of recurrence, along with grade and previous recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We describe distinct clinical outcomes and recurrence rates associated with meningioma molecular subgroups. Our findings emphasize the importance of genomic characterization to guide postoperative management decisions for meningiomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noaa226","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T15:42:56Z","timestamp":1602517376000},"page":"783-794","source":"Crossref","is-referenced-by-count":143,"title":["Associations of meningioma molecular subgroup and tumor recurrence"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1044-8015","authenticated-orcid":false,"given":"Mark W","family":"Youngblood","sequence":"first","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle F","family":"Miyagishima","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Jin","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Gupte","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Li","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China"},{"name":"The Third Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Duran","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Neurosurgery, University of Mississippi Medical Center, Jackson, Mississippi, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio D","family":"Montejo","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Section of Neurosurgery, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Zhao","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Sheth","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeniya","family":"Tyrtova","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Neurological Surgery, The University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"\u00d6zduman","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Acibadem Mehmet Ali Ayd\u0131nlar University, School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Iacoangeli","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Neurosurgery, Pitie-Salpetriere Hospital and Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Peyre","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Pitie-Salpetriere Hospital and Sorbonne University, Paris, France"},{"name":"Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Boetto","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Pitie-Salpetriere Hospital and Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Pease","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Pitie-Salpetriere Hospital and Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timu\u00e7in","family":"Av\u015far","sequence":"additional","affiliation":[{"name":"Department of Medical Biology, Bah\u00e7e\u015fehir University (BAU) Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Huttner","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaya","family":"Bilguvar","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Yale Center for Genome Analysis, Yale University West Campus, Orange, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00fcrker","family":"Kilic","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, BAU, School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Necmettin","family":"Pamir","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Acibadem Mehmet Ali Ayd\u0131nlar University, School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nduka","family":"Amankulor","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Kalamarides","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Pitie-Salpetriere Hospital and Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Zeynep","family":"Erson-Omay","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"G\u00fcnel","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Yale Center for Genome Analysis, Yale University West Campus, Orange, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Moliterno","sequence":"additional","affiliation":[{"name":"Yale Program in Brain Tumor Research, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"issue":"Suppl 1","key":"2021050522365635400_CIT0001","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.21037\/cco.2017.06.01","article-title":"Radiation therapy for WHO grade I meningioma","volume":"6","author":"Day","year":"2017","journal-title":"Chin Clin Oncol."},{"issue":"6","key":"2021050522365635400_CIT0002","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"6123","key":"2021050522365635400_CIT0003","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science."},{"issue":"10","key":"2021050522365635400_CIT0004","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ng.3651","article-title":"Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas","volume":"48","author":"Clark","year":"2016","journal-title":"Nat Genet."},{"issue":"3","key":"2021050522365635400_CIT0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet."},{"issue":"5","key":"2021050522365635400_CIT0006","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nov316","article-title":"Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma","volume":"18","author":"Abedalthagafi","year":"2016","journal-title":"Neuro Oncol."},{"key":"2021050522365635400_CIT0007","first-page":"1","article-title":"Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas [published online ahead of print October 25, 2019]","author":"Youngblood","year":"2019","journal-title":"J Neurosurg."},{"key":"2021050522365635400_CIT0008","doi-asserted-by":"crossref","first-page":"14433","DOI":"10.1038\/ncomms14433","article-title":"Integrated genomic analyses of de novo pathways underlying atypical meningiomas","volume":"8","author":"Harmanc\u0131","year":"2017","journal-title":"Nat Commun."},{"issue":"3","key":"2021050522365635400_CIT0009","first-page":"345","article-title":"SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas","volume":"19","author":"Boetto","year":"2017","journal-title":"Neuro Oncol."},{"issue":"5","key":"2021050522365635400_CIT0010","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"2021050522365635400_CIT0011","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0090-3019(03)00575-5","article-title":"The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas","volume":"61","author":"Takahashi","year":"2004","journal-title":"Surg Neurol."},{"issue":"3-4","key":"2021050522365635400_CIT0012","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/BF01403594","article-title":"Recurrences in meningioma after surgery","volume":"100","author":"Gupta","year":"1989","journal-title":"Acta Neurochir (Wien)."},{"issue":"2","key":"2021050522365635400_CIT0013","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3171\/2016.8.JNS161076","article-title":"Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas","volume":"127","author":"Strickland","year":"2017","journal-title":"J Neurosurg."},{"issue":"7","key":"2021050522365635400_CIT0014","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/modpathol.2016.81","article-title":"Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system","volume":"29","author":"Yuzawa","year":"2016","journal-title":"Mod Pathol."},{"issue":"15","key":"2021050522365635400_CIT0015","first-page":"3226","article-title":"Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity","volume":"58","author":"Sulman","year":"1998","journal-title":"Cancer Res."},{"issue":"4","key":"2021050522365635400_CIT0016","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/gcc.2870090411","article-title":"Allelic loss at 1 p is associated with tumor progression of meningiomas","volume":"9","author":"Bello","year":"1994","journal-title":"Genes, Chromosomes and Cancer."},{"issue":"2","key":"2021050522365635400_CIT0017","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bpa.12110","article-title":"High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression","volume":"24","author":"Goutagny","year":"2014","journal-title":"Brain Pathol."},{"issue":"12","key":"2021050522365635400_CIT0018","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/neuonc\/noy104","article-title":"TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma","volume":"20","author":"Spiegl-Kreinecker","year":"2018","journal-title":"Neuro Oncol."},{"issue":"5","key":"2021050522365635400_CIT0019","doi-asserted-by":"crossref","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2015","journal-title":"J Nat Cancer Inst."},{"issue":"1","key":"2021050522365635400_CIT0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3171\/jns.1985.62.1.0018","article-title":"Meningioma: analysis of recurrence and progression following neurosurgical resection","volume":"62","author":"Mirimanoff","year":"1985","journal-title":"J Neurosurg."},{"issue":"8","key":"2021050522365635400_CIT0021","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/neuonc\/nox018","article-title":"Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1\/2 activation and reduced time to tumor recurrence","volume":"19","author":"Yesil\u00f6z","year":"2017","journal-title":"Neuro Oncol."},{"issue":"2","key":"2021050522365635400_CIT0022","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/carcin\/bgr260","article-title":"Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses","volume":"33","author":"Kishida","year":"2012","journal-title":"Carcinogenesis."},{"issue":"3","key":"2021050522365635400_CIT0023","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00401-017-1678-x","article-title":"Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma","volume":"133","author":"Olar","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"7","key":"2021050522365635400_CIT0024","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/neuonc\/noz061","article-title":"DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management","volume":"21","author":"Nassiri","year":"2019","journal-title":"Neuro Oncol."},{"issue":"5","key":"2021050522365635400_CIT0025","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00401-018-1899-7","article-title":"DMD genomic deletions characterize a subset of progressive\/higher-grade meningiomas with poor outcome","volume":"136","author":"Juratli","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2021050522365635400_CIT0026","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00401-019-02008-w","article-title":"Mutational patterns and regulatory ne2rks in epigenetic subgroups of meningioma","volume":"138","author":"Paramasivam","year":"2019","journal-title":"Acta Neuropathol."},{"issue":"4","key":"2021050522365635400_CIT0027","first-page":"535","article-title":"Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas","volume":"19","author":"Shankar","year":"2017","journal-title":"Neuro Oncol."},{"issue":"1","key":"2021050522365635400_CIT0028","doi-asserted-by":"crossref","first-page":"13537","DOI":"10.1038\/s41598-018-31659-0","article-title":"An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures","volume":"8","author":"Collord","year":"2018","journal-title":"Sci Rep."},{"issue":"13","key":"2021050522365635400_CIT0029","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1016\/j.celrep.2018.03.013","article-title":"Comprehensive molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation","volume":"22","author":"Vasudevan","year":"2018","journal-title":"Cell Rep."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaa226\/36171254\/noaa226.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/5\/783\/37851751\/noaa226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/5\/783\/37851751\/noaa226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T14:01:22Z","timestamp":1620309682000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/23\/5\/783\/5928913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,10,17]]},"published-print":{"date-parts":[[2021,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaa226","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,10,17]]}}}